European Leukemia Trial Registry
Trial: MDS 5-azacitidine (Vidaza)

More Details
Scientific Title Treatment of imminent haematological relapse in patients with AML and MDS following allogeneic stem cell transplantation with 5-azacitidine (Vidaza®)
Short Title MDS 5-azacitidine (Vidaza)
Trialgroup NN
Type of Trial prospective, open-label, pilot study
Disease Stem cell transplantation(SCT) AML
Acute myeloid leukemia(AML) Stem cell transplantation
Stem cell transplantation(SCT) MDS
Myelodysplastic Syndrome(MDS) Stem cell transplantation
Age >= 18 years
Status Closed
Start of Recruitment 19.10.2006
Leader Platzbecker, Prof. Dr. med., Uwe
Contactperson

Study Physician
Weller, Dr. med., Denise
Tel: +49 (0)351 458 5134
Fax: +49 (0)351 458 5799
Email: Denise.Weller@uniklinikum-dresden.de

Biometrics
Schwanebeck, Uta
Tel: +49 (0)351 458 5134
Email: uta.schwanebeck@kksdresden.de

Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol
Remark Inclusion only for patients with CD34 pos. AML or MDS
created 05.03.2007 Deniz Gökbuget
changed 05.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org